DEC 24, 2015 10:32 AM PST

Immunotherapy Better for Non-Small-Cell Lung Cancer Patients

WRITTEN BY: Kara Marker
Some tumor cells in patients with non-small-cell lung cancer (NSCLC) express programmed death ligand 1 (PD-L1) that binds to its receptor (PD-1) which is expressed by immune cells. This interaction inhibits T cells’ ability to attack cancerous cells, allowing the tumor to grow unimpeded (Oncology). In attempt to block this inhibition, scientists are developing an immunotherapy that targets PD-1 and allows T cells to properly fight off growing cancer cells.

From the University of California, Los Angeles, researchers studied a group of patients with NSCLC to see how PD-1 immunotherapy compares with traditional chemotherapy.  Out of over a thousand participants, 75 percent had at least one percent of PD-L1 expressed by their tumor cells. The study results, which were published in The Lancet, showed groups of NSCLC patients receiving the PD-1 immunotherapy both experienced significant tumor shrinkage and lived longer than the patients who received chemotherapy.

"For most patients, this now offers data showing that immunotherapy leads to superior clinical outcomes with a side effect profile that is generally favorable to our traditional therapies," said Dr. Edward Garon, senior author of the paper.

Indeed, PD-1 immunotherapy utilizes the antibody pembrolizumab, which is significantly less toxic to cancer patients than chemicals used in chemotherapy.

NSCLC like squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are the most common types of lung cancer, making up 85 percent of all cases of lung cancer (American Cancer Society). Lung cancer is the leading cause of cancer death.

"This treatment provides real hope of long-lasting responses," Garon added.

For more about lung cancer, watch the following video.

Source: University of California, Los Angeles
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 14, 2021
Genetics & Genomics
RSV Infections Can Modify Host Immune Gene Activity
OCT 14, 2021
RSV Infections Can Modify Host Immune Gene Activity
Respiratory syncytial virus (RSV) are thought to be incredibly common; research has suggested that almost everyone is ev ...
NOV 11, 2021
Immunology
Malaria Researchers Make a Surprising Antibody Find
NOV 11, 2021
Malaria Researchers Make a Surprising Antibody Find
Researchers looking into the immunology of malaria infections have made an unexpected find that could ultimately lead to ...
NOV 10, 2021
Health & Medicine
Zinc for Respiratory Infections
NOV 10, 2021
Zinc for Respiratory Infections
With zinc sales climbing during the pandemic and in vitro studies showing the mineral fights respiratory viruses, includ ...
NOV 30, 2021
Immunology
Sweet Escape: A Sugar Molecule Helps HIV Remain Incognito
NOV 30, 2021
Sweet Escape: A Sugar Molecule Helps HIV Remain Incognito
HIV is a master of disguise. Once the virus enters the body, it has a number of sophisticated mechanisms through which i ...
JAN 17, 2022
Microbiology
Research Suggests Epstein Barr Virus Can Cause Multiple Sclerosis
JAN 17, 2022
Research Suggests Epstein Barr Virus Can Cause Multiple Sclerosis
Multiple sclerosis (MS) is a chronic autoimmune disease that impacts nearly 3 million people around the world. The cause ...
JAN 18, 2022
Immunology
Omicron Can't Dodge T Cells
JAN 18, 2022
Omicron Can't Dodge T Cells
The Omicron variant was first reported in November 2021. More recently, a surge of infections worldwide has led to wides ...
Loading Comments...